Surgical Innovations Group PLC CE mark validation indicated for CELLIS range (0597Z)
August 29 2018 - 1:00AM
UK Regulatory
TIDMSUN
RNS Number : 0597Z
Surgical Innovations Group PLC
29 August 2018
Surgical Innovations Group plc
("SI", "the Company" or the "Group")
CE mark validation indicated for CELLIS range
Surgical Innovations Group plc (AIM: SUN), the designer and
manufacturer of innovative medical technology for minimally
invasive surgery, provides an update relating to the CELLIS range
of products supplied to its UK distribution business, Elemental
Healthcare Limited ("Elemental") by Meccellis Biotech SA
("Meccellis").
Following the withdrawal of their previously held CE mark,
Meccellis have today announced that they have received confirmation
of their new CE mark for the complete CELLIS range of biological
matrix products used in breast and abdominal wall reconstruction
surgery from their Notified Body, PCBC. This enables Meccellis and
Elemental to resume selling the CELLIS range of products.
Further to this, Elemental and Meccellis have entered into an
extended agreement providing Elemental with exclusive UK
distribution rights in respect of the CELLIS range for a period of
three years expiring in June 2021, with a subsequent automatic
renewal period of two years, subject to meeting minimum purchase
obligations. This agreement, and the new CE mark, cover some
exciting and innovative new products which are due for launch in
the UK market during 2019.
Formal certification is anticipated within four to eight weeks,
during which period Group management are working closely with
Meccellis to optimise inventory logistics for the UK market. The
Elemental sales team will engage with UK customers during this time
to facilitate orderly replenishment of CELLIS products once
availability information becomes clear.
A further update will be provided in due course, and a trading
update will be issued together with the Company's interim results
for the six-month period ended 30 June 2018 on Tuesday 11 September
2018.
This announcement includes inside information as defined by
Article 7 of the Market Abuse Regulation No. 596/2014 and is
disclosed in accordance with the Company's obligations under
Article 17 of those Regulations.
For further information please contact:
Surgical Innovations Group plc www.sigroupplc.com
Nigel Rogers, Executive Chairman Tel: 0113 230 7597
Melanie Ross, COO & CFO
WH Ireland Limited (NOMAD & Broker) Tel: 0113 394 6600
Tim Feather
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCVVLFLVVFLBBV
(END) Dow Jones Newswires
August 29, 2018 02:00 ET (06:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Apr 2024 to May 2024
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From May 2023 to May 2024